AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUN 223 min read$AVBP

ArriVent BioPharma, Inc. (AVBP): Submission of Matters to a Vote of Security Holders

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001868279 0001868279 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
SEC EDGAR 8-K
Published Jun 22, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 22, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$AVBP
Neutral
high confidence
Mentioned
$AVBP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AVBPNeutralLow
01

Why it matters

This is a procedural disclosure of director elections and independent auditor ratification; it does not introduce new financial guidance, trial data, or corporate transactions.

02

Market read

Confirms governance continuity (board and auditor) with no stated operational or financial catalyst.

03

What to watch

Traders may still check the referenced April 28, 2026 proxy statement for any contested items or governance changes not captured in this 8-K summary.

Relevance 6/10Novelty 2/10Timing: after-hours/filing date (June 22, 2026) for the June 18 annual meeting results

Background

The company’s 8-K (Item 5.07) summarizes matters voted on at its June 18, 2026 annual stockholders meeting.

Company-level read

Ticker impact

$AVBPNeutralHigh confidence
Context

ArriVent BioPharma filed an 8-K reporting stockholder votes: directors elected and PricewaterhouseCoopers ratified for FY2026.

Expected impact

Low near-term impact; any reaction likely muted unless investors were expecting a contested outcome.

Evidence & confidence

The filing discloses election/ratification vote counts without new strategy, financing, clinical, or regulatory developments.

Market effects

Sector

Minimal; governance/auditor ratification does not alter biotech sector risk materially.

Regional

Minimal; US-listed microcap governance update with no stated operational change.

Global

Minimal; no cross-border deal, regulator action, or supply-chain event mentioned.

Counterpoint

What could challenge this read

If there had been a surprise auditor vote or director contest, it could signal governance risk; however, the disclosed results appear straightforward.

Key entities

  • company
    ArriVent BioPharma, Inc.

    Nasdaq-listed biotech whose annual meeting voting results were reported on Form 8-K.

  • auditor
    PricewaterhouseCoopers LLP

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

  • directors
    James Healy, M.D., Ph.D.; John Hohneker, M.D.; Stuart Lutzker, M.D., Ph.D.

    Elected to the board as Class II directors for terms serving until the 2029 annual meeting.

Read at source← All news

Related articles

OCT 6
HighAI 9/10

ArriVent collapses on disappointing lung cancer data

ArriVent BioPharma's lung cancer drug, furmonertinib, failed to meet its main goal in a late-stage study, missing a key benchmark in tumor progression. The company's shares fell over 50% in pre-market trading. CEO Bing Yao stated the company will review the data to determine next steps. The drug is approved in China for certain lung cancers, but the study's failure may limit its market potential.

finance.yahoo.com2 min
OCT 6
$AVBPHighAI 8/10

Why is Arrivent Biopharma stock collapsing today?

Arrivent Biopharma (AVBP) shares dropped 56.7% in pre-market trading after its Phase 3 FURVENT trial failed to meet the primary endpoint of progression-free survival for firmonertinib. The 240mg dose showed a median PFS of 11.0 months vs. 9.5 months for chemotherapy, but the hazard ratio was not statistically significant. CEO Bing Yao noted the disappointing results and the company is evaluating next steps.

investing.com1 min
OCT 6
$AVBPHighAI 8/10

ArriVent stock tumbles 60% after trial misses primary endpoint

ArriVent BioPharma's (AVBP) stock dropped 63% after its Phase 3 FURVENT trial for firmonertinib failed to meet the primary endpoint of progression-free survival in NSCLC patients. The trial compared two doses of firmonertinib against chemotherapy, with neither dose achieving statistical significance. Secondary endpoints showed some clinical benefit, but the company expressed disappointment in the results. The trial enrolled 398 patients globally.

investing.com2 min
OCT 6
$AVBPHighAI 9/10

ArriVent: Phase 3 FURVENT misses primary PFS endpoint by BICR; signals on secondary endpoints

ArriVent's Phase 3 FURVENT trial of firmonertinib missed the primary PFS endpoint by BICR (p=0.0654). The 240mg arm showed median PFS of 11.0 months vs. 9.5 months for control. Investigator-assessed PFS favored 240mg (11.1 vs. 7.1 months). Confirmed ORR by BICR was 60% for 240mg, 35% for 160mg, and 33% for control. Safety data were consistent with prior studies.

tradingview.com2 min
OCT 6
$AVBPMedAI 9/10

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC NEWTOWN SQUARE, PA, October 6, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage

SEC EDGAR 8-K2 min